EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a ...

For UK-based patients with Type 1 diabetes, the Dexcom G6 rtCGM device is associated with significant improvements in clinical outcomes [1],[2] and is highly-cost effective over patient lifetimes ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

The company will unveil Dexcom Smart Basal, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

DexCom (DXCM) saw its shares drop by more than 5% intra-day today. This decline comes amidst reports by analysts at JPMorgan and Piper Sandler regarding the potential effects of Medicare's exploration ...

PURCHASE, NY and SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the first and only comprehensive virtual care system, and DexCom, Inc., the leader in real-time ...

For people with diabetes treated with insulin, Dexcom rtCGM is associated with significant improvements over patients’ lifetimes and is likely to be cost-saving to the NHS DexCom, Inc.

The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...

VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...